Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.

Marie-France Savard, Daniel Yick Chin Heng, Jeffrey Graham et al.|Journal of Clinical Oncology|2019

Cited by 1